Explore › Outcome › Myopathy

Outcome

Myopathy

Also known as: Disorder of muscle Disorder of skeletal AND/OR smooth muscle Disorder of skeletal AND/OR smooth muscle (disorder) MUSCLE DIS MUSCULAR DIS Muscle Disorder Muscle Disorders Muscular Disease Muscular Diseases Myopathic Condition Myopathic Conditions Myopathic disease +9 more

3 findings 1 paper 3 related entities View in graph →

Related entities

interventions

conditions

studys

Findings (27)

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

None

null

Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated

Effect: null; 40.1% vs 40.5%

Size: 40.1% vs 40.5%

PMC4509601

Finding details → · Paper → · Graph →

Papers (1)

PMC4509601 · PMC →